The Key Differences Among DC, LAK, and NK Immunotherapies—and How to Choose
In the field of immunotherapy, DC (Dendritic Cell), LAK (Lymphokine-Activated Killer), and NK (Natural Killer) cell therapies each serve distinct purposes. Proper selection depends primarily on the tumor’s location, its potential for spread or metastasis, and the patient’s goals for preventing recurrence. Below is an overview of these three major approaches:
Dendritic Cell Vaccine Therapy: Insights from Dr. Yoichi Kato, Immunotherapy Specialist
In the human body, monocytes are produced in the bone marrow, travel through the bloodstream, and develop into dendritic cells in locations such as the lymph nodes. Serving as the “command center” of our immune system, dendritic cells collaborate with various lymphocytes to identify and combat foreign invaders, including viruses.
Japan’s Leading Expert in Immunotherapy: Dr. Yoichi Kato
Japan has long been at the forefront of immunotherapy, having initiated research in the 1970s and steadily advancing to become a global leader in the field. Dr. Yoichi Kato established the Shin-Yokohama Kato Clinic in 2008 and has since amassed one of the largest clinical databases of immunocellular therapies in Japan. With over 25 international journal publications and several authored books, Dr. Kato is a recognized authority whose expertise spans both research and real-world clinical applications.
